UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/634,574	08/05/2003	Ramin Shiekhattar	WSTR-0014C	1505
7590 09/10/2007 Licata & Tyrrell P.C. 66 E. Main Street			EXAMINER	
			HOLLERAN, ANNE L	
Marlton, NJ 08053			ART UNIT	PAPER NUMBER
			1643	
			MAIL DATE	DELIVERY MODE
			09/10/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
	10/634,574	SHIEKHATTAR, RAMIN				
Office Action Summary	Examiner	Art Unit				
•	Anne L. Holleran	. 1643				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with	the correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period was really received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNIC 36(a). In no event, however, may a repvill apply and will expire SIX (6) MONT, cause the application to become ABA	ATION.  oly be timely filed  HS from the mailing date of this communication.  NDONED (35 U.S.C. § 133).				
Status						
1)⊠ Responsive to communication(s) filed on <i>08 Au</i>	ugust 2007.					
2a) This action is <b>FINAL</b> . 2b) ⊠ This						
3) Since this application is in condition for allowar	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under E	x parte Quayle, 1935 C.D.	11, 453 O.G. 213.				
Disposition of Claims						
4) Claim(s) 13 is/are pending in the application.	un from consideration					
5) Claim(s) is/are allowed.	4a) Of the above claim(s) is/are withdrawn from consideration.					
6) Claim(s) 13 is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or	r election requirement.					
Application Papers	•					
9) The specification is objected to by the Examine	r					
10) The drawing(s) filed on is/are: a) acce		v the Examiner				
Applicant may not request that any objection to the						
Replacement drawing sheet(s) including the correct						
11) ☐ The oath or declaration is objected to by the Ex	aminer. Note the attached	Office Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. §	119(a)-(d) or (f).				
a) All b) Some * c) None of:	,					
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents	2. Certified copies of the priority documents have been received in Application No					
<ol><li>Copies of the certified copies of the prior</li></ol>	ity documents have been r	eceived in this National Stage				
application from the International Bureau		•				
* See the attached detailed Office action for a list	of the certified copies not re	eceived.				
Attachment(s)		•				
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)		ımmary (PTO-413) /Mail Date				
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	_	ormal Patent Application				

1. The amendment filed 8/8/2007 is acknowledged. Claims 4-6 were canceled. Claim 13, previously indicated as allowable, is pending. However, in view of newly discovered references, the finality of the previous Office action is withdrawn and prosecution on the merits continues.

## Claim Rejections Withdrawn:

- 2. The rejection of claims 4-6 under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement, for new matter, is withdrawn in view of the cancellation of claims 4-6.
- 3. The rejection of claim 5 under 35 U.S.C. 102(b) as being anticipated by Pradier (Pradier, O., et al, J. Cancer Res. Clin. Oncol. 125: 20-27, 1999) as evidenced by Chen (Chen, J.-J. et al, Cancer Research, suppl., 159: 1752s-1756s, 1999) is withdrawn in view of the cancellation of claim 5.
- 4. The rejection of claim 6 under 35 U.S.C. 102(b) as being anticipated by Blagosklonny Blagosklonny, M.V., et al. Cancer Res. 55(20): 4623-4626, 1995) as evidenced by Chen (Chen, J.-J. et al, Cancer Research (suppl., 159: 1752s-1756s, 1999) and also as evidenced by Saramaki (Saramaki, A. et al., Nucleic Acids Research, 34(2): 543-554, 2006) is withdrawn in view of the cancellation of claim 6.

Art Unit: 1643

New Grounds of Rejection:

#### Claim Objections

5. Claim 13 is objected to because of the following informalities: the term BRCC36 is misspelled as "RBCC36" in line 5 of claim 13. Appropriate correction is required.

# Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

6. Claim 13 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 13 refers to methods for identifying an agent that inhibits the expression of "BRCC36" or "BRE protein". The specification appears to limit BRCC36 to a protein with the sequence of SEQ ID NO: 10 and to limit BRE to a protein with the sequence SEQ ID NO: 9 (see page 5, lines 20-22). However, Ching (Ching, A.K.K. et al., Biochemical and Biophysical Research Communications, 288: 535-545, 2001) teaches that BRE is a protein of multiple isoforms (see abstract). Furthermore, on page 15 of the specification, BRCC36 is identified as SEQ ID NO: 9, and BRE/BRCC45 as SEQ ID NO: 8. Therefore, it is not clear if the terms in the claims "BRCC36" or "BRE" are narrow in scope, i.e. limited to single species, or if the terms are broader in scope, including isoforms, or homologous proteins from other species.

Application/Control Number: 10/634,574 Page 4

Art Unit: 1643

### Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

7. Claim 13 is rejected under 35 U.S.C. 102(e) as being anticipated by Chiu (US 2007/0010434 A1; effective filing date of 9/16/2002).

Please note that for claim 13, provisional applications 60/401,433 and 60/449,950 do not disclose a method comprising contacting a cell expressing BRE protein with a test compound. Therefore, the effective filing date for this claim is that of the instant application, 8/05/2003.

Chiu teaches SEQ ID NO: 262 (PRO84699; see page 58, line 4, 1<sup>st</sup> column), and teaches a method of comprising contacting a cell expressing a PRO protein with a test agent that may be an antisense molecule and monitoring the ability of the test agent to alter the expression of a PRO protein (see claims 24 and 25). The following sequence alignment between SEO ID NO: 9 and SEQ ID NO: 262 of Chiu shows that the PRO84699 is the same as the BRE of the instant claims. Thus, Chiu teaches a method that is the same as that claimed.

```
US-10-528-260B-262
; Sequence 262, Application US/10528260B
; Publication No. US20070010434A1
```

RESULT 2

<sup>;</sup> GENERAL INFORMATION: APPLICANT: Chiu, Henry

APPLICANT: Clark, Hilary

APPLICANT: Dennis, Kathryn

APPLICANT: Fong, Sherman

APPLICANT: Schoenfeld, Jill R.

APPLICANT: Wood, William I.

Art Unit: 1643

```
APPLICANT: Wu, Thomas D.
  TITLE OF INVENTION: Compositions And Methods For Treating Immune Disorders
  FILE REFERENCE: P1983R1
  CURRENT APPLICATION NUMBER: US/10/528,260B
  CURRENT FILING DATE: 2005-03-16
  PRIOR APPLICATION NUMBER: US 60/411,392
  PRIOR FILING DATE: 2002-09-16
  PRIOR APPLICATION NUMBER: PCT/US03/029097
  PRIOR FILING DATE: 2003-09-15
  NUMBER OF SEQ ID NOS: 506
SEQ ID NO 262
   LENGTH: 415
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-528-260B-262
 Ouerv Match
                    100.0%; Score 2240; DB 5; Length 415;
 Best Local Similarity 100.0%; Pred. No. 2.9e-210;
 Matches 415; Conservative
                        0; Mismatches
                                       0; Indels
Qу
         1 MSPEVALNRISPMLSPFISSVVRNGKVGLDATNCLRITDLKSGCTSLTPGPNCDRFKLHI 60
           1 MSPEVALNRISPMLSPFISSVVRNGKVGLDATNCLRITDLKSGCTSLTPGPNCDRFKLHI 60
        61 PYAGETLKWDIIFNAQYPELPPDFIFGEDAEFLPDPSALQNLASWNPSNPECLLLVVKEL 120
Qу
           Db
        61 PYAGETLKWDIIFNAQYPELPPDFIFGEDAEFLPDPSALQNLASWNPSNPECLLLVVKEL 120
Qу
        121 VQQYHQFQCSRLRESSRLMFEYQTLLEEPQYGENMEIYAGKKNNWTGEFSARFLLKLPVD 180
           121 VQQYHQFQCSRLRESSRLMFEYQTLLEEPQYGENMEIYAGKKNNWTGEFSARFLLKLPVD 180
Db
        181 FSNIPTYLLKDVNEDPGEDVALLSVSFEDTEATQVYPKLYLSPRIEHALGGSSALHIPAF 240
Qу
           Db
       181 FSNIPTYLLKDVNEDPGEDVALLSVSFEDTEATQVYPKLYLSPRIEHALGGSSALHIPAF 240
        241 PGGGCLIDYVPQVCHLLTNKVQYVIQGYHKRREYIAAFLSHFGTGVVEYDAEGFTKLTLL 300
Ov
           241 PGGGCLIDYVPQVCHLLTNKVQYVIQGYHKRREYIAAFLSHFGTGVVEYDAEGFTKLTLL 300
        301 LMWKDFCFLVHIDLPLFFPRDQPTLTFQSVYHFTNSGQLYSQAQKNYPYSPRWDGNEMAK 360
Qy
           301 LMWKDFCFLVHIDLPLFFPRDQPTLTFQSVYHFTNSGQLYSQAQKNYPYSPRWDGNEMAK 360
Db
        361 RAKGCQGSRDACSPWEQVLAFAVAKTGCKLLQPQRNWPSSRGPPWRASEGERTAQ 415
Qу
           Db
        361 RAKGCQGSRDACSPWEQVLAFAVAKTGCKLLQPQRNWPSSRGPPWRASEGERTAQ 415
```

#### Conclusion

No claim is allowed.

Application/Control Number: 10/634,574 Page 6

Art Unit: 1643

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Anne Holleran, whose telephone number is (571) 272-0833. The

examiner can normally be reached on Monday through Friday from 9:30 am to 5:00 pm. If

attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry

Helms, can be reached on (571) 272-0832. Any inquiry of a general nature or relating to the

status of this application or proceeding should be directed to the Group receptionist whose

telephone number is (571) 272-1600.

Papers related to this application may be submitted to Group 1600 by facsimile

transmission. The faxing of such papers must conform to the notice published in the Official

Gazette, 1096 OG 30 (November 15, 1989). The Official Fax number for Group 1600 is (571)

273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private

PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll free).

Anne L. Holleran

Patent Examiner
September 5, 200

LANA M. WARRIS, PH.D.

PRIMARY EXAMINER